Dyadic International’s (DYAI) Buy Rating Reiterated at Noble Financial
Noble Financial reaffirmed their buy rating on shares of Dyadic International (NASDAQ:DYAI) in a research note published on Monday morning, AnalystRatings.com reports. They currently have a $9.00 price objective on the biotechnology company’s stock.
Separately, TheStreet upgraded Social Reality from a d+ rating to a c- rating in a research note on Wednesday, April 17th.
DYAI stock traded down $0.15 during midday trading on Monday, hitting $5.63. The company’s stock had a trading volume of 51,900 shares, compared to its average volume of 95,545. Dyadic International has a 1 year low of $1.40 and a 1 year high of $7.30. The stock has a market cap of $153.89 million, a P/E ratio of -33.06 and a beta of 0.29.
In other Dyadic International news, VP Ronen Tchelet sold 20,000 shares of the business’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $6.11, for a total value of $122,200.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
About Dyadic International
Dyadic International, Inc, a biotechnology platform company, engages in the development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, bi-specific antibodies, fab antibody fragments, FC-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.
Further Reading: How is the discount rate different from the Federal Funds rate?
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.